acute myeloid leukemia | 2 Minute Medicine

Surgical site anesthetic infusion may enhance analgesia after mastectomy

Quizartinib improves overall median survival in patients with acute myeloid leukemia

May 25, 2023

1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion ...

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

byDavid Xiangand1 others

May 13, 2022

0

1. Compared to placebo and azacytidine, the combination of ivosidenib and azacitidine demonstrated significant clinical benefit for IDH1-mutated acute myeloid ...

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

byKathleen Lau

November 27, 2021

0

$#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates$

#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates

byKathleen Lau

September 30, 2021

0

#VisualAbstract Ivosidenib or enasidenib combined with intensive chemotherapy were well-tolerated and showed encouraging clinical activity in newly diagnosed mIDH1/mIDH2 acute myeloid leukemia

byKathleen Lau

April 25, 2021

0

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

byKathleen Lau

January 22, 2021

0

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

byKathleen Lau

January 15, 2021

0

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

byNeel Mistryand1 others

December 23, 2020

0

1. Older age, progressive disease status, diagnosis of acute myeloid leukemia, non-Hodgkin lymphoma, or plasma cell neoplasms, and severe or ...

$#VisualAbstract: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML$

#VisualAbstract: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

byConstance Wu

November 30, 2019

0

1. In this phase 3 trial, patients with relapsed or refractory acute myeloid leukemia who received gilteritinib had a longer ...

Quick Take: Factors associated with successful discontinuation of immune suppression after allogenic hematopoietic cell transplantation

Gilteritinib more effective than salvage chemotherapy for FLT3-mutated acute myeloid leukemia

byThomas Suand1 others

November 23, 2019

0

1. In this phase 3 trial, patients with relapsed or refractory acute myeloid leukemia who received gilteritinib had a longer ...

Tag: acute myeloid leukemia

Quizartinib improves overall median survival in patients with acute myeloid leukemia

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates

#VisualAbstract Ivosidenib or enasidenib combined with intensive chemotherapy were well-tolerated and showed encouraging clinical activity in newly diagnosed mIDH1/mIDH2 acute myeloid leukemia

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Gilteritinib more effective than salvage chemotherapy for FLT3-mutated acute myeloid leukemia

Recent Reports